LAS VEGAS -- Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., announces that its patented antimicrobial hand sanitizer demonstrated a greater than 99 percent kill in laboratory studies against the Influenza A virus.
"Our studies performed at an FDA compliant laboratory confirm that our antimicrobial hand sanitizer product may help in preventing the spread of the Influenza A virus caused from hand to hand and surface to hand contact," says Skinvisible's CEO Terry Howlett.
Manufactured for and marketed by Michigan based Dermal Defense, Inc., this antimicrobial hand sanitizer incorporates Skinvisible's proprietary Invisicare polymer delivery system. Notable, proven advantages of the formulation include its ability to adhere to the skin, thereby forming a protective bond. It resists both wash-off and perspiration while holding the active ingredient Triclosan on the skin for extended periods of time.
The product, marketed as Dermal Defense, offers the added advantage of being alcohol-free. "Alcohol-based sanitizers typically provide instant protection but offer no long-term persistence," says Howlett. "These products require frequent reapplication, which is inconvenient for most people and because alcohol dries the skin, it can cause adverse reactions." Although proven to be effective on its own, Howlett notes that Dermal Defense is specifically designed to be a complementary adjunct to hand washing rather than a replacement.
The simplest way to avoid the flu is to stay away from crowds during an epidemic but this is easier said than done. "By incorporating Dermal Defense Antimicrobial Hand Sanitizer into a daily hygiene regime, one may reduce the risk of contracting Influenza A and other serious viral and bacterial infections," says Howlett. "It is especially recommended for people who regularly frequent schools, hospitals, athletic facilities, airports, shopping centers and other large public facilities."
Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic, and skincare products. In addition, Skinvisible formulates and manufactures products for private label customers.
Source: Skinvisible, Inc.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.